Omeprazole, currently marketed as Prilosec and generic omeprazole, has been shown to reduce gastric acid secretion in animals and man. It reduces the secretion of acid by inhibiting the proton pump of the parietal cell (Fellenius et al., 1981). Omeprazole was not designed as a prodrug. It was first synthesized by Junggren et al. (1981) along with 29 other derivatives of substituted 2-(2-benzimidazolyl)-pyridines and was found to have more potent gastric acid secretion inhibitory effects in dogs than did previously tested structurally related compounds. However, omeprazole was later found not to be the active inhibitor of the proton pump per se. Instead, it acts as a prodrug and is converted to the active inhibitor in the acidic compartments of the parietal cell, near the enzymes it inhibits (Lindberg et al., 1986).
Unable to display preview. Download preview PDF.
- Baldwin JE, Adlington RM, and Crouch NP. Process for the Preparation of Omeprazole and Intermediate Compounds. Eur Patent EP 899268, 1999: 8 pGoogle Scholar
- Brandstrom AE. Method for Synthesis of Omeprazole. Int Patent WO 9118895 1991: 11 pGoogle Scholar
- Brandstrom AE, Lindberg P, Bergman NA, Alminger T, Ankner K, Junggren U, Lamm B, Nordberg P, and Erickson M. Chemical Reactions of omeprazole and Omeprazole Analogs. I. A Survey of the Chemical Transformations of Omeprazole and its Analogs. Acta Chem Scand 1989; 43:536–548Google Scholar
- Correia PB, Romao CC, Correia LB, Pereira MF, Fernandes AC, Borges JE, Tavares R, Costa MDC, and Teixeira F. New Method for the Preparation of the Anti-Ulcer Compounds Omeprazole, Lansoprazole and Pantoprazole. Int Patent WO 2003097606, 2003:21 pGoogle Scholar
- Junggren UK, and Sjöstand SE. Gastric Acid Secretion Inhibiting Substituted 2-(2-Benzimidazolyl)-pyridines, Pharmaceutical Preparations Containing Same, and Methods for Inhibiting Gastric Acid Secretion. US Patent 4255431, 1981:10pGoogle Scholar
- Senn-Bilfinger J, Krueger U, Sturm E, Figala V, Klemm K, Kohl B, Rainer G, Schaefer H, and Blake TJ. (H+−K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 2. The Reaction Cascade Induced by Treatment with Acids. Formation of 5H-Pyrido[1′,2′:4,5][1,2,4]Thiadiazino[2,3-a]benzimidazol-13-ium Salts and Their Reactions with Thiols. J Org Chem 1987;52: 4582–4592CrossRefGoogle Scholar
- Slemon C, and Macel B. Preparation of Omeprazole and Lansoprazole Via Oxidation of Amide Thioether, Hydrolysis of Sulfinyl Amide, and Decarboxylation of Sulfinyl Carboxylate. US Patent 5374730, 1994:6 pGoogle Scholar
- Smahovsky V, Oremus V, Heleyova K, Zlatoidsky P, Gattnar O, Varga I, Stalmach V, Jezek L, Slovakofarma AS, Slovakia, Gattnar O, Stalmach, and Valdemar JL. Method of Omeprazole Preparation. Int Patent WO 9809962 1998:10 pGoogle Scholar
- Sturm E, Krueger U, Senn-Bilfinger J, Figala V, Klemm K, Kohl B, Rainer G, Schaefer H, Blake, and Timothy J. (H+−K+)-ATPase Inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 1. Their Reaction with Thiols Under Acidic Conditions. Disulfide Containing 2-Pyridiniobenzimidazolides as Mimics for the Inhibited Enzyme. J Org Chem 1987; 52: 4573–4581CrossRefGoogle Scholar